QPX7728

Key Takeaways

• Xeruborbactam inhibits serine and metallo β‑lactamases
• Broad-spectrum β‑lactamase inhibitor restores β‑lactam efficacy
• Phase 1 combination trials underway with oral prodrug
• SAR optimization addressed oxidative liabilities
• Potentiates multiple β‑lactams in preclinical models

Summary

Xeruborbactam (QPX‑7728) is a broad‑spectrum β‑lactamase inhibitor designed to revive the activity of β‑lactam antibiotics against multidrug‑resistant Gram‑negative bacteria. Developed by Qpex Biopharma and Shionogi, the molecule targets both serine‑ and metallo‑β‑lactamases, addressing a key resistance mechanism. Preclinical data show it enhances multiple partner β‑lactams in vitro and improves outcomes in animal infection models. The compound and its oral prodrug have entered Phase 1 combination studies with selected β‑lactams.

Pulse Analysis

The rise of carbapenem‑resistant Enterobacterales and other Gram‑negative pathogens has outpaced the pipeline of new antibiotics, leaving clinicians reliant on older β‑lactams that are increasingly neutralized by β‑lactamases. In this landscape, inhibitors that can simultaneously block serine‑based and metallo‑β‑lactamases are especially valuable, because they broaden the spectrum of rescue agents and simplify regimen design. Xeruborbactam’s dual‑coverage approach directly tackles this gap, offering a pharmacological lever to extend the life of existing β‑lactam drugs.

Chemically, xeruborbactam derives from a cyclopropane boronate scaffold, a motif known for high affinity to the active sites of diverse β‑lactamases. Qpex’s medicinal chemistry program applied extensive structure‑activity relationship (SAR) work to enhance potency while mitigating oxidative degradation—a common liability of boronic acids. The result is an oral prodrug that delivers the active inhibitor systemically, improving patient convenience and adherence compared with intravenous-only options. This design reflects a broader industry shift toward oral resistance‑breaking agents that can be co‑prescribed with standard β‑lactam regimens.

Clinically, the transition to Phase 1 combination studies marks a pivotal step. By pairing xeruborbactam with established β‑lactams, developers aim to demonstrate safety, pharmacokinetic synergy, and early efficacy signals. If successful, the product could capture a sizable share of the $10‑plus billion global market for anti‑resistance therapies, competing with other pipeline inhibitors such as vaborbactam and relebactam. Moreover, the oral formulation could differentiate QPX‑7728 in hospital‑to‑outpatient pathways, potentially reshaping treatment algorithms for complicated urinary and respiratory infections caused by resistant Gram‑negative bacteria.